TY - JOUR
T1 - Re-evaluating inclusion criteria for autologous hematopoietic stem cell transplantation in advanced systemic sclerosis: Three successful cases and review of the literature
AU - Shah, Ankoor
AU - Spierings, Julia
AU - van Laar, Jaap
AU - Sullivan, Keith M
N1 - Publisher Copyright:
© The Author(s) 2021.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
Publisher Copyright:
© The Author(s) 2021.
PY - 2021/6
Y1 - 2021/6
N2 - Systemic sclerosis is a chronic autoimmune disease with a poor prognosis, particularly when a patient has rapidly progressive skin or pulmonary involvement. Autologous hematopoietic stem cell transplant is an emerging treatment for this condition, that has been demonstrated to be more effective than immunosuppressants. Careful selection of patients has reduced the transplant-related mortality and maximized the likelihood of benefit. In this report, we present three cases of successful autologous hematopoietic stem cell transplant in patients who would not have met inclusion criteria for entrance into the completed hematopoietic stem cell transplant. After >18 months of follow-up, three patients had clinically significant benefit in terms of skin tightening and pulmonary function tests. Future studies of hematopoietic stem cell transplant in systemic sclerosis may aim to carefully liberalize inclusion criteria to include patients who may not have otherwise been treated while still maintaining an acceptable safety profile.
AB - Systemic sclerosis is a chronic autoimmune disease with a poor prognosis, particularly when a patient has rapidly progressive skin or pulmonary involvement. Autologous hematopoietic stem cell transplant is an emerging treatment for this condition, that has been demonstrated to be more effective than immunosuppressants. Careful selection of patients has reduced the transplant-related mortality and maximized the likelihood of benefit. In this report, we present three cases of successful autologous hematopoietic stem cell transplant in patients who would not have met inclusion criteria for entrance into the completed hematopoietic stem cell transplant. After >18 months of follow-up, three patients had clinically significant benefit in terms of skin tightening and pulmonary function tests. Future studies of hematopoietic stem cell transplant in systemic sclerosis may aim to carefully liberalize inclusion criteria to include patients who may not have otherwise been treated while still maintaining an acceptable safety profile.
KW - Systemic sclerosis
KW - autoimmune disease
KW - autologous hematopoietic stem cell transplant
KW - case report
KW - interstitial lung disease
UR - http://www.scopus.com/inward/record.url?scp=85100191806&partnerID=8YFLogxK
U2 - 10.1177/2397198320985766
DO - 10.1177/2397198320985766
M3 - Review article
SN - 2397-1983
VL - 6
SP - 199
EP - 205
JO - Journal of Scleroderma and Related Disorders
JF - Journal of Scleroderma and Related Disorders
IS - 2
ER -